Dr Reddy's Bets on Semaglutide and Biosimilars for FY28 Recovery
Dr Reddy's is looking to semaglutide and biosimilars to support a recovery in FY28. September-quarter growth in domestic formulations was offset by lower North American Revlimid sales and weakness in APIs.